Table 2.
Univariate analysis of enrolled patients
| Variables | Mean ± SD/N (%) | Disease-free survival | Cancer-specific survival |
|---|---|---|---|
| HR (95% CI), P value | HR (95% CI), P value | ||
| Postoperative capecitabine duration | 4.65 ± 6.75 | 0.91 (0.86, 0.98), 0.014 | 0.90 (0.84, 0.97), 0.0043 |
| 0 | 143 (55.64%) | 1.0 | 1.0 |
| ≤ 12 weeks | 79 (30.74%) | 0.52 (0.36, 0.98), 0.030 | 0.48 (0.24, 0.99), 0.046 |
| ≤ 24 weeks | 35 (13.62%) | 0.26 (0.19, 0.70), 0.007 | 0.09 (0.01, 0.67), 0.018 |
| Gender | |||
| Male | 161 (62.65%) | 1.0 | 1.0 |
| Female | 96 (37.35%) | 1.07 (0.58–1.68), 0.21 | 1.12 (0.60, 2.08), 0.73 |
| Age (years) | 75.83 ± 4.60 | 1.04 (0.73–1.44), 0.77 | 1.06 (0.99, 1.12), 0.080 |
| ≥ 70, < 75 | 114 (44.36%) | 1.0 | 1.0 |
| ≥ 75, < 80 | 84 (32.68%) | 1.23 (0.73–2.88), 0.079 | 1.57 (0.77, 3.19), 0.21 |
| ≥ 80 | 59 (22.96%) | 1.42 (0.75–3.13), 0.23 | 1.79 (0.83, 3.87), 0.14 |
| T stage | |||
| 1–2 | 11 (4.28%) | 1.0 | 1.0 |
| 3 | 211 (82.10%) | 1.40 (0.65–5.35), 0.42 | 1.30 (0.31, 5.44), 0.71 |
| 4 | 35 (13.62%) | 1.22 (0.92–5.57), 0.069 | 1.13 (0.23, 5.62), 0.88 |
| N stage | |||
| 0 | 128 (49.81%) | 1.0 | 1.0 |
| 1 | 104 (40.47%) | 1.10 (0.67–3.64), 0.45 | 1.77 (0.85, 3.67), 0.13 |
| 2 | 25 (9.73%) | 4.04 (1.93–8.99), < 0.0001 | 5.31 (2.42, 11.64), < 0.0001 |
| Stage | |||
| II | 128 (49.81%) | 1.0 | 1.0 |
| III | 129 (50.19%) | 2.19 (1.13, 4.66), 0.017 | 2.45 (1.26, 4.78), 0.0083 |
| Histological type | |||
| Common type | 221 (85.99%) | 1.0 | 1.0 |
| Special type | 36 (14.01%) | 1.28 (0.75–2.96), 0.061 | 1.69 (0.83, 3.44), 0.15 |
| CEA | |||
| Normal | 163 (63.42%) | 1.0 | 1.0 |
| Elevated | 94 (36.58%) | 1.29 (0.88–2.42), 0.38 | 1.15 (0.62, 2.12), 0.66 |
| CA199 | |||
| Normal | 209 (81.64%) | 1.0 | 1.0 |
| Elevated | 47 (18.36%) | 2.68 (1.98–3.93), 0.0075 | 2.04 (1.04, 3.98), 0.037 |
| Charlson comorbidity index | |||
| ≤ 4 | 197 (76.65%) | 1.0 | 1.0 |
| > 4 | 60 (23.35%) | 1.18 (0.61–3.09), 0.87 | 1.05 (0.50, 2.19), 0.90 |
| MMR status | |||
| dMMR | 20 (7.78%) | 1.0 | 1.0 |
| pMMR | 185 (71.98%) | 0.79 (0.42, 1.93), 0.57 | 0.51 (0.21, 1.23), 0.1338 |
| Unknown | 52 (20.23%) | 0.67 (0.29, 1.84), 0.12 | 0.63 (0.22, 1.76), 0.3769 |
Abbreviations: HR hazard ratio; CI confidence interval; CA carcinoma antigen; CEA carcinoembryonic antigen; MMR mismatch repair; dMMR mismatch repair deficiency; pMMR proficient mismatch repair